Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

Fortrea Holdings Inc. (FTRE) SEC Filings & Earnings Calls

EquiReason read 14 Fortrea Holdings Inc. SEC filings in the last 12 months. Latest: 8-K on 2026-09-30 — Appointment of Carrie Russell as Chief Accounting Officer, effective October 5, 2026; compensation details provided..

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

FTREFortrea Holdings Inc.Follow FTRE — free
Biotechnology · Healthcare
—
Price chart with a free account
Market cap
2.2B
P/E TTM
—
Dividend yield
—
52-week
—
Next earnings
29 Oct, in 5 days

Every filing, read

last 12 months · SEC

What happened, the numbers inside, guidance and risks. The original is one click away.

30 Sep 20268-K · 5.02Appointment of Carrie Russell as Chief Accounting Officer, effective October 5, 2026; compensation details provided.open

Risks flagged

No material risk; routine executive appointment.

“No disagreements or material interests disclosed.”
Read the original on SEC EDGAR ↗
10 Sep 20268-K · 5.02Fortrea reinstated Jason Knoblauch as CFO after a temporary restraining order was lifted. David Smith stepped down as Interim CFO but remains on the board. The prior legal dispute with Knoblauch's former employer was settled.open

Risks flagged

Legal dispute with former employer resolved but indicates potential non-compete/restrictive covenant risks

“lawsuit filed by Mr. Knoblauch’s prior employer against him and the Company alleging that Mr. Knoblauch violated certain restrictive covenants and retained confidential information” · word for word
Read the original on SEC EDGAR ↗
29 Jul 202610-QQuarterly revenue declined 4.5% YoY; direct cost ratio improved 170 bps; operating cash flow turned positive.earningsopen

Figures in the filing · each found in the filing text

Revenue · Q2-2026$678M-5% y/y
Backlog · 2026-06-30$7.80B
Cash and Cash Equivalents · 2026-06-30$169M
Operating Cash Flow · H1-2026$12M
Capital Expenditures · H1-2026$17M

Risks flagged

Revenue Decline and FSP Demand Weakness

“The 4.9% decrease in organic revenues was due to lower pass through costs as well as lower demand for our functional service provider business.” · word for word

Customer Cancellation Risk

“The majority of our contracts contain early termination provisions that typically require notice periods ranging from 30 to 90 days.” · word for word
Read the original on SEC EDGAR ↗
29 Jul 20268-K · 2.02, 5.02Revenue $678M (-4% y/y); Book-to-bill ratio 1.06; Backlog $7.80B; Guidance: Revenue $2,620M-$2,690M; Adjusted EBITDA $205M-$220Mearningsopen

Figures in the filing · each found in the filing text

Revenue · Q2-2026$678M-5% y/y
Book-to-bill ratio · Q2-2026$1.06
Backlog · Q2-2026$7.80B
Adjusted EBITDA · Q2-2026$59M+7% y/y
Adjusted net income · Q2-2026$23M+29% y/y
Adjusted diluted EPS · Q2-2026$0.23+21% y/y
GAAP net loss · Q2-2026$-13M
Operating cash flow · Q2-2026$29M
Free cash flow · Q2-2026$20M

Guidance

Revenue $2,620M-$2,690M; Adjusted EBITDA $205M-$220M

Increased full-year 2026 guidance reflecting confidence in business momentum and execution.

Risks flagged

Revenue declined 4.5% YOY, though adjusted profitability improved.

“Revenue $678.2M vs $710.3M prior year, down 4.5%”

GAAP net loss persists, though significantly improved from prior year.

“GAAP net loss $(13.2)M vs $(374.9)M prior year (includes goodwill impairment)”
Read the original on SEC EDGAR ↗
14 Jul 20268-K · 5.02Reported a director or officer change (departure, election, appointment or pay arrangement)open

Risks flagged

Key finance leadership departures may disrupt financial reporting and controls.

“CAO and CFO both transitioning; interim appointments.”
Read the original on SEC EDGAR ↗
26 Jun 20268-K · 5.02, 7.01Reported the departure of a director or principal officer (CEO/CFO change); issued a Regulation FD disclosure (forward guidance or material update)SEC ↗
5 May 202610-QRevenues $636M (-2% y/y); Direct costs as a % of revenues 80.6; Selling, general and administrative expenses $100M (-18% y/y)open

Figures in the filing · each found in the filing text

Revenues · Q1-2026$637M-2% y/y
Direct costs as a % of revenues · Q1-202680.6%
Selling, general and administrative expenses · Q1-2026$101M-18% y/y
Backlog · 2026-03-31$7.80B
Cash and cash equivalents · 2026-03-31$148M+45% y/y
Net cash used for operating activities · Q1-2026$-17M+86% y/y
Capital expenditures · Q1-2026$8M+176% y/y

Risks flagged

Revenue decline from FSP demand weakness

“The 3.2% decrease in organic revenues was due to lower pass through costs as well as lower demand for our functional service provider business.” · word for word

Backlog cancellation risk

“Our backlog also reflects any cancellation or adjustment activity related to these awards.” · word for word
Read the original on SEC EDGAR ↗
5 May 20268-K · 2.02Revenues $636M (-2% y/y); Book-to-bill ratio 1.15; Adjusted EBITDA $47M (+55% y/y); Guidance: Revenue $2,550M-$2,650M, adj EBITDA $190M-$220Mearningsopen

Figures in the filing · each found in the filing text

Revenues · Q1-2026$637M-2% y/y
Book-to-bill ratio · Q1-2026$1.15
Adjusted EBITDA · Q1-2026$47M+55% y/y
Adjusted net income · Q1-2026$15M+700% y/y
Adjusted diluted EPS · Q1-2026$0.16+700% y/y
Backlog · Q1-2026$7.85B

Guidance

Revenue $2,550M-$2,650M, adj EBITDA $190M-$220M

Full year guidance affirmed. Strong Q1 performance with improving book-to-bill and margins.

Risks flagged

Revenue slightly declined year-over-year.

“Revenue $636.5M vs $651.3M in Q1 2025.”
Read the original on SEC EDGAR ↗
27 Apr 2026DEF 14AAnnual proxy statement filed, disclosing executive compensation, governance, and 2025 financial performance including CEO transition and goodwill impairment.open

Figures in the filing · each found in the filing text

Revenue · FY2025$2.72B
Adjusted EBITDA · FY2025$190M-6% y/y
Backlog · 2025-12-31$7.73B+0% y/y
Book-to-bill ratio · FY2025$1.02
Net loss from continuing operations · FY2025$-986M
Goodwill and other asset impairment · FY2025$798M
Debt paydown · FY2025$76M
Net savings · FY2025$93M
Employees · 2025-12-3114,300
Shares outstanding · 2026-04-1594,584,730

Risks flagged

Goodwill impairment risk

“Goodwill and other asset impairment 797.9” · word for word

CEO transition risk

“In May 2025, Mr. Pike stepped down as the Company's Chief Executive Officer...the Board appointed Mr. Neupert...to succeed Mr. Pike as Interim CEO...Mr. Thakral assumed the Chief Executive role in August 2025.” · word for word

Restructuring risk

“Restructuring and other charges 49.1”

Spin-related costs risk

“One-time spin-related costs 24.7”
Read the original on SEC EDGAR ↗
26 Feb 20268-K · 2.02Revenue $2.72B (+1% y/y); Adjusted EBITDA $190M (-6% y/y); Backlog $7.73B; Guidance: FY2026 revenue $2,550M-$2,650M vs FY2025 $2,723.4M; adjusted EBITDA $190M-$220M vs $189.9Mearningsopen

Figures in the filing · each found in the filing text

Revenue · FY2025$2.72B+1% y/y
Adjusted EBITDA · FY2025$190M-6% y/y
Backlog · Q4-2025$7.73B
Book-to-bill ratio · Q4-2025$1.14
GAAP net loss · FY2025$-986M
Cash and cash equivalents · Q4-2025$175M
Operating cash flow · FY2025$114M
Free cash flow · FY2025$88M

Guidance

FY2026 revenue $2,550M-$2,650M vs FY2025 $2,723.4M; adjusted EBITDA $190M-$220M vs $189.9M

Revenue guidance cut indicates expected decline, but backlog and book-to-bill show some demand stability. Margin guidance roughly flat.

Risks flagged

Revenue decline guidance indicates demand weakness in CRO market.

“FY2026 revenue guidance midpoint $2,600M vs FY2025 actual $2,723.4M.”

Goodwill impairment of $797.9M in H1 2025 signals past overvaluation and market cap decline.

“non-cash goodwill impairment charge of $797.9 million recognized in the first half of 2025” · word for word
Read the original on SEC EDGAR ↗
26 Feb 202610-KRevenue $2.72B (+1% y/y); Direct costs as % of revenue 81.5; Goodwill impairment $798Mopen

Figures in the filing · each found in the filing text

Revenue · FY2025$2.72B+1% y/y
Direct costs as % of revenue · FY202581.5%
Goodwill impairment · Clinical Development · FY2025$798M
Cash and cash equivalents · 2025-12-31$175M+47% y/y
Operating cash flow · FY2025$114M-57% y/y
Capital expenditures · FY2025$25M-1% y/y

Risks flagged

Goodwill impairment risk

“Goodwill impairment for 2025 was $797.9. The impairment was specific to the Clinical Development reporting unit.” · word for word

Revenue concentration on clinical development

“lower clinical development revenues resulting primarily from the mix of complex and longer duration studies in our portfolio as well as lower functional service provider revenue” · word for word

Margin pressure from pass-through costs

“Direct costs increased 2.7% in 2025, as compared with 2024, and increased as a percentage of revenues to 81.5% in 2025, as compared to 80.2% in 2024.” · word for word
Read the original on SEC EDGAR ↗
20 Nov 20258-K · 7.01Fortrea Holdings Inc. announces expiration of debt tender offer to purchase up to $75.744M of its 7.500% Senior Secured Notes due 2030; accepted $75.743M aggregate principal amount at a proration factor of 0.154199.open

Figures in the filing · each found in the filing text

aggregate principal amount of notes tendered · 2025-11-18$76M

Risks flagged

Debt tender offer reduces leverage but may signal liquidity management or refinancing needs.

“tender offer to purchase for cash up to $75,744,000 of outstanding 7.500% Senior Secured Notes due 2030”
Read the original on SEC EDGAR ↗
5 Nov 202510-QFortrea reported Q3 2025 revenue of $701.3M, up 3.9% YoY, but gross margin contracted significantly due to higher pass-through costs.earningsopen

Figures in the filing · each found in the filing text

Revenue · Q3-2025$701M+4% y/y
Operating cash flow · 9M-2025$-16M
Cash and cash equivalents · Q3-2025$131M
Backlog · Q3-2025$7.60B

Risks flagged

Goodwill impairment risk

“During the first and second quarters of 2025, due to sustained declines in our share price and uncertainties in global macroeconomic conditions, we determined that indicators of impairment existed.” · word for word

Margin pressure from pass-through costs

“Direct costs increased as a percentage of revenues to 82.5% during the three months ended September 30, 2025 as compared to 78.0% in the corresponding period in 2024.” · word for word
Read the original on SEC EDGAR ↗
5 Nov 20258-K · 2.02Revenue $701M (+4% y/y); GAAP net loss $-16M; Adjusted EBITDA $51M (-21% y/y); Guidance: Revenue raised to $2.7B-$2.75B; adjusted EBITDA narrowed to $175M-$195Mearningsopen

Figures in the filing · each found in the filing text

Revenue · Q3-2025$701M+4% y/y
GAAP net loss · Q3-2025$-16M
Adjusted EBITDA · Q3-2025$51M-21% y/y
GAAP diluted loss per share · Q3-2025$-0.17
Adjusted diluted earnings per share · Q3-2025$0.12
Backlog · Q3-2025$7.64B
Book-to-bill ratio · Q3-2025$1.13
Year-to-Date Revenue · 9M-2025$2.06B+3% y/y
Year-to-Date Adjusted EBITDA · 9M-2025$136M-7% y/y

Guidance

Revenue raised to $2.7B-$2.75B; adjusted EBITDA narrowed to $175M-$195M

Revenue guidance raised on strong backlog; EBITDA guidance narrowed but lower than prior expectations; margin pressure from cost structure.

Risks flagged

Goodwill impairment of $797.9M due to share price decline and discount rate increase, indicating potential further asset write-downs.

“Year-to-Date GAAP net loss was $(953.7) million, inclusive of a non-cash goodwill impairment charge of $797.9 million.” · word for word

Adjusted EBITDA declining despite revenue growth suggests margin pressure from cost structure or pricing.

“Third quarter adjusted EBITDA was $50.7 million, compared to third quarter of 2024 adjusted EBITDA of $64.2 million.” · word for word

Macroeconomic and market-driven discount rate increase impacting valuation; customer concentration and international operations risks.

“The goodwill impairments primarily resulted from declines in the Company’s share price, as well as a macroeconomic market-driven increase to the discount rate.”
Read the original on SEC EDGAR ↗

Fortrea Holdings Inc. — questions

What did Fortrea Holdings Inc. file recently?
14 SEC filings in the last 12 months. Latest: 8-K on 2026-09-30 — Appointment of Carrie Russell as Chief Accounting Officer, effective October 5, 2026; compensation details provided.

Every figure on this page comes from Fortrea Holdings Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.